Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells

@inproceedings{Harris2011PololikeK1,
  title={Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells},
  author={Peter S Harris and Sujatha L Venkataraman and Irina Alimova and Diane K. Birks and Andrew M. Donson and Jeffrey A. Knipstein and Adrian M. Dubuc and Michael D. Taylor and Michael Hillel Handler and Nicholas K. Foreman and Rajeev Vibhakar},
  booktitle={BMC Cancer},
  year={2011}
}
Medulloblastoma is the most common malignant brain tumor in children and remains a therapeutic challenge due to its significant therapy-related morbidity. Polo-like kinase 1 (PLK1) is highly expressed in many cancers and regulates critical steps in mitotic progression. Recent studies suggest that targeting PLK1 with small molecule inhibitors is a promising approach to tumor therapy. We examined the expression of PLK1 mRNA in medulloblastoma tumor samples using microarray analysis. The impact of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Targeting Polo-like Kinase 1 Enhances Radiation Efficacy for Head-and-neck Squamous Cell Carcinoma

International journal of radiation oncology, biology, physics • 2010
View 11 Excerpts
Highly Influenced

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Nature Reviews Drug Discovery • 2010
View 4 Excerpts
Highly Influenced

Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 4 Excerpts
Highly Influenced

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 4 Excerpts
Highly Influenced

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 2 Excerpts

Medulloblastoma comprises four distinct molecular variants.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 7 Excerpts

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…